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ABSTRACT: Introduction: To test the surface fixation method contrasting urine samples of women with 
GDM vs healthy pregnant women. Methods: This was a pilot descriptive study. Three groups were 
conformed: A) Pregnant women with GDM, B) Women with healthy pregnancies and C) Non-pregnant healthy 
women. The positiveness of the surface fixation method was contrasted with Odds Ratio. Results: 12 women 
with GDM, 14 with healthy pregnancies and 9 non-pregnant women were included in the study.The OR for a 
positive surface fixation test when contrasting GDM vs Healthy pregnancies was of 2.7 while the value when 
contrasting GDM vs Healthy pregnancies + Non pregnant women was of 3.2 without reaching significant 
statistical difference in any case. Conclusion: the surface fixation method used with urine samples, suggests the 
existence of a transient antigen-antibody reaction that contributes to the inefficient insulin secretion. 
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INTRODUCTION: 
 
Gestational diabetes mellitus (GDM) is still a clinical 
challenge around the world1. Inflammation 
contributes to its pathogenesis but the precise 
underlying mechanism remains to be explored2. 
Furthermore, autoimmunity is increasingly being 
recognized as a pathogenic component of 
GDM3,although the identification of possible 
implicated autoantibodies is ongoing. For example, 
higher fT3 levels, potentially resulting from de novo 
synthesis or increased fT4 to fT3 conversion, may be 
an indicator of GDM risk starting early in 
pregnancy4. 
 
 
 
 
 
It is recognized that the action of autoimmune aspects 
in GDM are not solely restricted to autoantibodies.On 
the contrary, they include a miss-regulation of the 
Th1/Th2 equilibrium5. In this line of research IL-37 
and 38 play important roles in autoimmunity, but 
their role in GDM development is unclear. The first 
may be protective, while the second, produced in the 
chorionic villi and umbilical cords, may be a 
response to local inflammation duringthe 
development of this pregnancy complication. Such a 
deregulated micro-environment may contribute to 
GDM development via an immune-mediated 
mechanism6. 
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Also concerning autoimmunity and GDM, evidence 
shows that in a number of women with GDM Zinc 
transporter 8 autoantibodies may be a marker for islet 
autoimmunity, but the clinical relevance of this 
finding requires further investigation7. Similarly, 
newer research underscores the importance of the 
maternal microbiome which may promote a pro-
inflammatory environment conducive to autoimmune 
and metabolic disturbance8. 
Omics sciences using urine as a sample have 
developed year after year9,10, but these advanced 
laboratory procedures are expensive and infeasible 
for developing countries. On the other hand, the 
surface fixation method developed by Ruiz 
Castañeda is based on immunoglobulins’ property of 
adhering firmly to the filter paper on which the 
antigen-antibody reaction takes place11. This 
technique has been successfully tested in several 
diseases12–14. The aim of this study was to test the 
Ruiz Castañeda surface fixation method contrasting 
urine samples of women with GDM and healthy 
pregnant women. 
  
MATERIAL AND METHODS: 
 
Study participants 
This was a pilot descriptive study. Pregnant women 
attendant at the Maternal-Fetal Service of the 
“Mónica Pretelini Sáenz” (HMPMPS), Health 
Institute of the State of Mexico (ISEM), Toluca, 
Mexico, were invited to take part. Three groups were 
formed: A) Pregnant women with GDM, B) Women 
with healthy pregnancies and C) Non-pregnant 
healthy women. GDM was diagnosed with a 75g oral 
glucose tolerance test. Women with multiple 
pregnancies, type 1 diabetes mellitus, glucose 
intolerance, and those with autoimmune or chronic 
diseases were excluded from the study. 
 
Anthropometric Measurements 
Weight (kg) was measured using a weight scale 
(SECA 711) and height (m) was measured using a 
mechanical column scale (SECA 220).With these two 
variables, the body mass index (BMI) (kg/m2) was 
calculated. 
 
Laboratory 
A total of 3mL of venous blood (Vacutainer tubes) 
was taken from thefasting subjects. The 
concentrations of glucose (mg/dL), total cholesterol 
(mg/dL), and triglycerides (mg/dL) were determined 
by enzymatic methods (Atellica® Solution, Siemens-
Healthineers) in the Clinical Laboratory of the 
HMPMPS. All measurements followed standardized 
procedures according to International Federation of 
Clinical Chemistry and Laboratory Medicine (IFCC). 
 
Surface fixation method 
In the Research Laboratory of the HMPMPS the 
urine sediment was obtained following these steps15: 
1. In a 1-L bottle, 250ml of ethanol 96% was 
placed. Then, the patient was asked to collect the 
first morning urine for three days.  
2. The container was left for 24 hours at room 
temperature to obtain a precipitate, and at the end 
of this time it was emptied, making a side hole to 
conserve the precipitate. 
 
In the Research Laboratory of the Faculty of 
Chemistry, Autonomous University of the State of 
Mexico (UAEMéx), the surface fixation method was 
performed following these steps: 
1. Once the sediment was obtained, it was 
centrifuged at 1500g for 3 minutes to separate the 
supernatant (Figure 1A). 
2. The sediment was diluted with 0.9% saline 
solution (5mL). This step was repeated if there 
was too much sediment (Figure 1B). 
3. The supernatant was placed in an Eppendorf tube 
so that the ethanol evaporated to the environment 
and the sediment was restored with 0.9% saline 
and stored (Figure 1C). 
4. A solution of (0.2% bromophenol) in a 50-ml 
flask was prepared. 0.1g of bromophenol was 
added and up to 50ml was filled with distilled 
water (Figure 1D). 
ISSN No. 2456-4400 
Int J Med Lab Res 2019, 4(3): 15-20 
 
 International Journal of Medical Laboratory Research (Vol. 4 Issue 3, December 2019)          www.ijmlr.com/IJMLR© All right are reserved   
 17 
5. Another fixative solution was prepared in a 100-
ml volumetric flask: 50ml of alcohol + 10ml of 
acetic acid + 40 ml of distilled water was added 
until the flask became warm (Figure 1D). 
6. A drop of urine from each patient was added to 
the filter paper (Figure 1E). 
7. The filter paper was taken to the stove for 5 
minutes at 30°C (Figure 1F). 
8. A drop of each patient's serum was placed on the 
drop of urine (Figure 1G). 
9. The 0.2% bromophenol solution was spread on 
the filter paper containing the urine and serum 
drops (Figure 1H). 
10. After waiting 1minute, the fixing solution was 
added to the same filter paper (Figure 1I). 
11. The filter paper was dried at room temperature 
for one hour. 
12. The last step was washing the filter paper with 
saline solution (Figure 1J). The results were 
observed and recorded. The urine of a patient 
with asthma was used as a positive control 
(Figure 2).  
 
 
 
Figure 1.Surface fixation method in urine samples. 
A) Sediment centrifugation. 
B) Sediment diluted with 0.9% saline solution. 
C) Supernatant evaporation and sediment is restored 
with 0.9% saline solution. 
D) Bromophenol and fixative solutions. 
E) Filter paper with a drop of urine. 
F) Filter paper taken to the stove for 5 minutes at 30°C. 
G) A drop of each patient's serum is placed on the drop 
of urine. 
H) The 0.2% bromophenol solution is spread on the 
filter paper containing the urine and serum. 
I) Fixing solution added to the filter paper. 
J) Filter paper washing with saline solution.  
 
 
 
 
Figure 2.Sample report explanation 
Sample 1: Healthy pregnant woman, Sample 2: 
Pregnant woman with Gestational Diabetes Mellitus, 
Sample 3: Non-pregnant healthy woman, Sample 4: 
Positive control. 
 
Statistical Analyses 
Age, anthropometric measurements and laboratorial 
tests were represented by measures of central 
tendency. First, the Kolmogorov test was performed 
to determine the normality of the variables. The one-
way ANOVA test was used to contrast the variables 
among the three groups, and Student's T test or the 
Mann Whitney U test were used for multiple 
comparisons. These statistical analyses were carried 
out in the SPSS program, version 14. Odds Ratio 
(OR) was calculated for the positive surface fixation 
test and the diagnosis of GDM using MEDCALC16.  
 
Ethics 
This study was approved by the Ethics and Research 
Committees of the HMPMPS (code 2017-06-532) 
and was performed in accordance with the ethical 
standards laid down in the updated Declaration of 
Helsinki, Fortaleza, Brazil, 2013. Informed consent 
was obtained from the patients. 
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RESULTS: 
 
Table 1 General characteristics of the patients 
Variable Group p 
GD
M 
(N = 
12) 
Healthy 
pregnancie
s 
(N = 14) 
Non 
pregnan
t women 
(N = 9) 
 
Age (years) 29.6 
± 6.9 
27.9 ± 9.6 23.4 ± 
5.9 
0.034
b
 
BMI (kg/m2) 26.1 
± 2.6 
27.2 ± 4.1 22.3 ± 
4.0 
0.049
b 
0.019c 
Cholesterol 
(mg/dL) 
159.3 
± 
39.3 
222.3 ± 51.2 165.5 ± 
34.9 
0.003a 
0.013c 
Triglyceride
s (mg/dL) 
198.2 
± 
105.7 
288 ± 111.4 110.8 ± 
32.1 
0.046a 
0.034
b 
≤ 
0.001c 
Glucose 
(mg/dL) 
179.1 
± 
43.6 
83.6 ± 9.6 82.3 ± 
4.4 
≤ 
0.001a 
≤ 
0.001
b
 
BMI: Body Mass Index, GDM: Gestational Diabetes Mellitus. 
a: between GDM and Healthy pregnancies. 
b: between GDM and Non pregnant women. 
c: between Healthy pregnancies and Non pregnant women. 
 
Table 2 Odds Ratio (OR) for positive surface fixation 
test between GDM and Healthy pregnancies 
T
est
 
G
D
M
 
H
ealthypr
eg
n
a
n
cies
 
O
R
 
 
(95%
 C
I)
 
Z
statistic
 
p
 
P
o
sitiv
e
 
10 9 2.7778 
(0.4278 
to 
18.0386) 
1.070 0.2845 
N
eg
ativ
e
 
2 5    
CI: Confidence Interval, GDM: Gestational Diabetes Mellitus, 
OR: Odds Ratio. 
 
 
 
 
Table 3 Odds Ratio (OR) for positive surface fixation 
test between GDM and Healthy pregnancies + Non 
pregnant women 
Test GD
M 
Healthy 
pregnan
cies +  
Non 
pregnan
t women 
OR  
(95% CI) 
Zstati
stic 
p 
Positive 10 14 3.2143 
(0.5677 to 
18.2004) 
1.320 0.1869 
Negative 2 9    
CI: Confidence Interval, GDM: Gestational Di 
 
Table 1 shows the general characteristics of the three 
groups: 12 with GDM, 14 with healthy pregnancies 
and 9 non-pregnant women. As expected, there was a 
clear difference in the glucose value, but due to two 
outlier values in the GDM group the cholesterol 
values were lower in the GDM than in the non-
pregnant women. 
 
Table 2 shows the OR for positive surface fixation 
test when contrasting GDM and Healthy pregnancies 
and Table 3 shows the same between GDM and 
Healthy pregnancies + Non pregnant women. In the 
first, the OR was of 2.7 and in the second the OR was 
of 3.2 without reaching significant statistical 
difference in any case. 
 
DISCUSSION: 
 
Immunomodulatory treatment from urine created by 
Dr. Ruiz Castañeda has been widely used to treat 
different diseases. For those academics only now 
reading about Ruiz Castañeda’s urine-based 
immunomodulation treatment, the process to obtain 
the preparation is as follows: 
1. After obtaining the urine sediment as explained 
previously, it is centrifuged, evaporated, 
suspended in saline, filtered andthen diluted. 
2. Sterility and culture tests are done to verify that 
the material is free of contaminants and can be 
used for treatment. 
3. Finally, it is packaged under the strictest aseptic 
measures. 
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The instructions for the treatment are (using an 
ultrafine point insulin syringe with injections in the 
arms or abdomen): 
1. Impregnation: Apply 10 units twice a week, 
increasing from ten units in ten-unit stepsuntil 
reaching 80 units. 
2. Maintenance: When reaching 80 units the 
application changes toonce a week until the 
proper antigen is finished. 
Although in clinical experience some patients 
improve, unfortunately there are no scientific 
publications to support these successful results. For 
that reason, our main effort was to confirm the 
isolation and bromophenol staining positiveness on 
the filter paper as it happened. 
Based on our results it can be confirmed that a water-
soluble substance was isolated from the urine of 
GDM patients which produced positive bromophenol 
staining. This preliminary report has been 
encouraging since all positive reactions were 
properly controlled with the serum of patients 
suffering from various clinical conditions.  
Our study could be improved by perfecting the 
process conditions of the technique, both in spin time 
and heat exposure time. A limitation of this initial 
approach is the low number of patients and also, it 
has to be said, the non-specificity of the result due to 
the possibility of isolating more than one antigen-
antibody reaction on the filter paper. 
Urine samples from patients with GDM have been 
studied in several ways, for example, the group of 
Guo et al. using iTRAQ (the isobaric tags for relative 
and absolute quantification) for quantitative 
proteomics found 83 differential proteins increased 
and 36 proteins decreased in GDM. They concluded 
that the two candidate protein biomarkers (CD59 and 
IL1RA) in urine could be early, noninvasive 
diagnostic predictors of GDM17. More recently, 
López-Hernández et al. analyzed the urinary 
metabolome profile of GDM patients in the 3rd 
trimester of pregnancy based on liquid 
chromatography mass spectrometry, and identified 14 
metabolites that were significantly up-regulated in  
the urine of GDM patients18. It is expected that using 
the above listed techniques it could be possible to 
identify, in a detailed way, the predominant 
molecules isolated through the surface fixation 
method for every disease in which the 
immunoglobulins’ property of adhering firmly to the 
filter paper on which the antigen-antibody reaction 
takes place could be used.  
In conclusion, the surface fixation method used with 
urine samples suggests, in the specific case of GDM, 
the existence of a transient antigen-antibody reaction 
that contributes to inefficient insulin secretion. 
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